Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/db mice

Diabetes

Volumn 55, Issue 1, 2006, Pages 240-248

  Harrity, Thomas ^a   Farrelly, Dennis ^a   Tieman, Aaron ^a   Chu, Cuixia ^a   Kunselman, Lori ^a   Gu, Liqun ^a   Ponticiello, Randolph ^a   Cap, Michael ^a   Qu, Fucheng ^a   Shao, Chunning ^a   Wang, Wei ^a   Zhang, Hao ^a   Fenderson, William ^a   Chen, Sean ^a   Devasthale, Pratik ^a   Jeon, Yoon ^a   Seethala, Ramakrishna ^a   Yang, Wen Pin ^a   Ren, Jimmy ^a   Zhou, Min ^a   Ryono, Denis ^a   Biller, Scott ^a,b   Mookhtiar, Kasim A ^a,c   Wetterau, John ^a,d   Gregg, Richard ^a   Cheng, Peter T ^a   Hariharan, Narayanan ^a   more..

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Advinus Therapeutics Private Limited Bangalore   (India)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; CORTICOSTERONE; FATTY ACID; FENOFIBRATE; GLUCOSE; INSULIN; LIPID; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC OBESITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN RELEASE; LIPID LIVER LEVEL; LONG TERM CARE; MALE; METABOLIC DISORDER; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; TIME; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 33644783769     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.01.06.db05-0648     Document Type: Article

References (47)

1. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405:421-424, 2000
2. Kliewer S, Xu E, Lambert M, Willson T: Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239-263, 2001
3. Berger J, Moller D: The mechanism of action of PPARs. Annu Rev Med 53:409-435, 2002
4. Bays H, Mandarino L, DeFronzo R: Mechanisms of endocrine disease: role of adipocytes, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, 2004
5. Olefsky J: Treatment of insulin resistance with PPARγ agonists. J Clin Inves 106:467-472, 2000
6. Lebovitz H: Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 (Suppl. 2):S23-S29, 2002
7. Robins S, Collins D, Wittes J, Papademetriou V, Deedwania P, Schaefer E, McNamara J, Kashyap M, Hershman J, Wexler L, Rubins H: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. J Am Med Assoc 285:1585-1591, 2001
8. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910, 2001
9. Buchan K, Hassall D: PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Med Res Rev 20:350-366, 2000
10. Duval C, Chinetti G, Trottein F, Fruchart J, Staels B: The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430, 2002
11. Beckman J, Creager M, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 287:2570-2581, 2002
12. Nesto R, Drexler A: Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus: proceedings of a symposium. November 6-8, 2002, New York, New York, USA. Am J Med 115 (Suppl. 1):1S-120S, 2003
13. Devasthale P, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity H, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau J, Biller S, Ryono D, Selan F, Hariharan N, Cheng PTW: Design and synthesis of N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl) ethoxy] phenyl]methyl] glycine [muraglitazar/BMS-298585), a novel PPARα/γ dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248-2250, 2005
14. Connor S, Hughes M, Moore G, Lister C, Smith S: Antidiabetic efficacy of BRL-49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse my non-invasive 1H NMR studies of urine. J Pharm Pharmacol 49:336-344, 1997
15. Diani A, Sawada G, Wyse B, Murray F, Khan M: Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endo Metab 286:E116-E122, 2004
16. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta F, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S: Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β-cells from oxidative stress. Metabolism 53:488-494, 2004
17. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti J, Heyman R: RXR agonists activates PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 18:272-276, 1998
18. Rossmeisl M, Rim J, Koza R, Kozak L: Variation in type 2 diabetes-related traits in mouse strains susceptible to diet induced obesity. Diabetes 52:1958-1966, 2003
19. Small G, Burdett K, Connock M: A sensitive spectrophotometric assay for peroxisomal acyl co-A oxidase. Biochem J 227:205-210, 1985
20. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
21. Yajima K, Hirose H, Fujita H, Seto Y, Ukeda K, Miyashita K, Kawai T, Yamamoto Y, Ogawa T, Yamada T, Saruta T: Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endo Met 284:E966-E971, 2003
22. Boettcher B, Fanelli B, Stephen Z, Caplan S, Sabio M: Comparison of ligand binding affinities in the mouse and human PPARα and γ ligand binding domains. Keystone Symposium-PPARs, 2003 (Abstract no. 106)
23. Petit D, Bonnefis M, Rey C, Infante R: Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis 74:215-225, 1988
24. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 10:2088-2093, 1998
25. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocrin Rev 26:439-451, 2005
26. Combs T, Wagner J, Berger J, Doebber T, Wang W, Zhang B, Tanen M, Berg A, O'Rahilly S, Savage D, Chatterjee K, Weiss S, Larson P, Gottesdiener K, Gertz B, Charron M, Scherer P, Moller D: Induction of adipocyte complement related protein of 30 Kd by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002
27. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno N, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
28. Pajvani U, Hawkins M, Combs T, Rajala M, Doebber T, Berger J, Wagner J, Wu M, Knopps A, Xiang A, Utzschneider K, Kahn S, Olefsky J, Buchanan T, Scherer P: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 279:12152-12162, 2004
29. Alberts P, Nilsson C, Selen G, Engblom L, Edling N, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson C, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen L: Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762, 2003
30. Nielsen M, Caumo A, Chandramouli V, Schumann W, Cobelli C, Landau B, Vilstrup H, Rizza R, Schmitz O: Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physio Endocrin Met 286:E102-E110, 2004
31. Lind P: Interdependence of hepatic lipid and glucose metabolism: novel pharmaceutical targets for diabetes. Curr Opin Investig Drugs 5:395-401, 2004
32. Bajaj M, Suraamornkul S, Hardies L, Pratipanawatr T, DeFronzo R: Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789, 2004
33. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadawaki T: A novel insulin sensitizer acts as coligand for PPARα and PPARγ: effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47:1841-1847, 1998
34. Etriglyceridesen G, Oldham B, Johnson W, Broderick C, Montrose C, Brozinick J, Misener E, Bean J, Bensch W, Brooks D, Shuker A, Rito C, McCarthy J, Ardecky R, Tyhonas J, Dana S, Bilakovics J, Paterniti J, Ogilvie K, Liu, Kauffman R: A tailored therapy for the metabolic syndrome: the dual PPARα/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51:1083-1087, 2002
35. Chakrabarti R, Vikramadithyan R, Misra P, Hiriyan J, Raichur S, Damarla R, Gershome C, Suresh J, Rajagopalan R: Ragaglitazar: a novel PPARα and PPARγ agonist with potent lipid-lowering and insulin sensitizing efficacy in animal models. Br J Pharmacol 140:527-537, 2003
36. Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes N, Ostling J, Camejo G: AZ-242, a novel PPARα/γ dual agonist with beneficial effect on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43:1855-1863, 2002
37. Pickavance L, Brand C, Wassermann K, Wilding J: The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144:308-316, 2005
38. Chaput E, Saladin R, Silvestre M, Edgar A: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Bioplys Res Commun 27:445-450, 2000
39. Guerre-Millo M, Gervois P, Rape E, Madsen L, Poulain P, Derudas B, Herbert J-M, Winegar D, Wilson T, Fruchart J-C, Berge R, Staels B: PPARα activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
40. Mosqueda-Garcia R, Frost C, Swaminathan A, Raymond R, Nepal S, Reeves R, Gregg R: Glucose lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPARα/γ dual agonist, in type 2 diabetic patients (Abstract). Diabetes 53 (Suppl. 2):A32, 2004
41. Gregg R, Swaminathan A, Frost C, Nepal S, Raymond R, Mosqueda-Garcia R: Muraglitazar, a novel PPARα/γ dual agonist, lowers fasting plasma glucose, triglycerides, NEFA and apoCIII after once a day administration in type 2 diabetic patients (Abstract no. 717). Abstract presented at the 40th Annual Meeting of the European Association for the Study of Diabetes, 5-9 September 2004, Munich, Germany
42. Frost C, Swaminathan A, Raymond R, Nepal S, Gregg R, Reeves R, Mosqueda-Garcia R: Lipid lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPARα/γ dual agonist, in type 2 diabetic patients (Abstract). Diabetes 53 (Suppl. 2):A475, 2004
43. Lebovitz H: Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 (Suppl. 2):S23-S29, 2002
44. Larsen T, Toubro S, Astrup A: PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27:147-161, 2003
45. Bergman R, Ader M: Free fatty acids and pathogenesis of type 2 diabetes mellitus. TEM 11:331-356, 2000
46. Buchanan T, Xiang A, Peters R, Kjos S, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis H, Azen S: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
47. Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E: Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc 291:1730-1737, 2004